Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,320,000 shares, a growth of 6.5% from the March 31st total of 1,240,000 shares. Based on an average daily trading volume, of 419,700 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.7% of the company’s shares are sold short.

Chimerix Price Performance

Shares of NASDAQ CMRX opened at $0.95 on Thursday. The stock has a market cap of $85.15 million, a P/E ratio of -1.00 and a beta of 1.15. Chimerix has a 1 year low of $0.88 and a 1 year high of $1.57. The firm has a 50-day moving average of $1.05 and a 200 day moving average of $1.00.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Chimerix had a negative return on equity of 37.93% and a negative net margin of 25,337.96%. Research analysts expect that Chimerix will post -0.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CMRX. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Chimerix in a report on Friday, March 1st. Wedbush reiterated an “outperform” rating and set a $6.00 target price on shares of Chimerix in a report on Monday, February 12th. Finally, StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a research report on Monday, March 4th.

Hedge Funds Weigh In On Chimerix

Several institutional investors and hedge funds have recently modified their holdings of CMRX. Vance Wealth Inc. purchased a new stake in Chimerix during the 4th quarter valued at about $46,000. Pale Fire Capital SE purchased a new stake in shares of Chimerix during the third quarter valued at approximately $95,000. Assenagon Asset Management S.A. increased its position in shares of Chimerix by 167.3% during the third quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 267,044 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Chimerix by 190.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 387,638 shares during the last quarter. Finally, Vestal Point Capital LP bought a new position in Chimerix in the 4th quarter valued at approximately $1,348,000. 45.42% of the stock is currently owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.